Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults

Inclusion Criteria:

- Males and females ≥ 65 years old who are healthy or have co-morbidities

- Individuals who or whose legal representative(s) have voluntarily given written
consent after the nature of the study has been explained according to local regulatory
requirements, prior to study entry

- Ability to attend all scheduled visits and to comply with study procedures including
Diary card completion and follow-up

Exclusion Criteria:

- History of behavioral or cognitive impairment or psychiatric condition

- Hypersensitivity, including allergy, to any component of vaccines, medicinal products
or medical equipment whose use is foreseen in this study

- Abnormal function of the immune system

- Receipt of any influenza vaccine within 6 months prior to enrollment in this study, or
plan to receive influenza vaccine prior to the Day 22 blood collection

- Any other clinical condition that, in the opinion of the Investigator, might interfere
with the results of the study or pose additional risk to the subject due to
participation in the study

Additional eligibility criteria may be discussed by contacting the site.